Pomerantz LLP is investigating Agios Pharmaceuticals and some of its executives for potential securities fraud following the company's announcement that its Phase 2 trial for the drug tebapivat in sickle cell disease did not meet expectations. The trial results led Agios to halt further development of the drug, causing the company's stock to drop 6.74% on July 21, 2026. The investigation aims to determine if Agios engaged in unlawful business practices that affected investors. Investors affected are encouraged to contact the law firm for possible class action participation.
Amundi conducted a share buyback program from July 27 to July 31, 2026, repurchasing a total of 200,000 shares. The average purchase price during this period was €90.90 per share. This move is part of Amundi's ongoing strategy to manage its capital s...
Amazon-owned Zoox has received federal approval to deploy the first steering-wheel-free robotaxis commercially in the U.S., pending state and local permissions. This milestone in autonomous vehicle technology introduces new legal challenges, especial...
Coface SA announced the total number of shares and voting rights composing its share capital as of July 31, 2026. The company has 150,179,792 shares and an equal number of theoretical voting rights, with 149,566,295 exercisable voting rights after de...
Coface SA disclosed its total number of shares and voting rights as of July 31, 2026. The company has 150,179,792 shares and the same number of theoretical voting rights, with 149,566,295 real voting rights excluding own shares. This update confirms ...
Linde reported record Q2 sales of $9.3 billion, a 9% increase year-over-year, and adjusted earnings per share rose 10% to $4.50, surpassing expectations. Growth was driven by higher prices, volume gains, and strong electronics sector sales, supported...
